Re-evaluation of chronic hepatitis B and hepatitis C patients lost to follow-up: results of the Northern Holland hepatitis retrieval project
Tóm tắt
Many persons infected with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) in the past are now lost to follow-up. The aim of the Northern Holland Hepatitis Retrieval Project (NHHRP) is to retrieve and re-evaluate persons previously diagnosed with HBV or HCV and bring them back into care. Chronic HBV infection was defined as two positive Hepatitis B surface antigen (HBsAg) tests within 6 months and chronic HCV infection with 2 positive HCV RNA tests by polymerase chain reaction (PCR). Data files of the local public health services and microbiology laboratory were explored to identify all registered HBV and HCV cases in the Alkmaar region, the Netherlands, for the past 15 years. Identified cases were compared with patients currently known in our hospital. Patients without follow-up in primary or hospital care were approached via their primary health care physician and invited for evaluation at our hospital In total, 552 cases of HBV were identified. 356 (64.5%) had no follow-up. Only 113/356 (31.7%) were eligible for retrieval and 44.2% were evaluated in our hospital resulting in a change of management in 22/50 (44%) of patients. Four hundred ninety nine cases of HCV were identified, 150/499 (30.1%) were lost to follow-up. Only 20/150 (13.3%) were eligible for retrieval and 4/20 (20%) were evaluated at our clinic. Resulting in a change of management in 3/4 (75%). Only a limited part of HBV and HCV persons lost to follow-up is eligible for retrieval, nonetheless re-evaluation of these persons will lead to a change of management in the majority of persons.
Tài liệu tham khảo
Organization WH. Global hepatitis report 2017. Geneva; 2017.
Dienstag JL. Hepatitis B virus infection. New Engl J Med. 2008;359:1486–500.
Rosen HR. Clinical practice. Chronic hepatitis C infection. New Engl J Med. 2011;364(25):2429–38.
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–68.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.
Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495–503.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
NIV N, NVMDL, NVH, NVZA. HCV Richtsnoer. 2017.
NVMDL. Richtlijn Behandeling van een chronische Hepatitis-B-virusinfectie 2012. Available from: https://www.mdl.nl/sites/www.mdl.nl/files/richlijnen/Richtlijn_HBV_nieuwe_inzichten_2012.pdf
Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Björnsson ES, Johannsson B, et al. Treatment as prevention for hepatitis C in Iceland (TRAP HEP C). A real-world experience from a nationwide elimination program using direct acting antiviral agents. J Hepatol. 2017;66(1):S72.
McDonald L, Cragie A, Schulberg J, Scarmozzino J, Papaluca T, Stoove M, et al. Outcomes of treatment for hepatitis C virus infection in the prison setting. J Hepatol. 2017;66(1):S70-71.
Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol. 2014;20(36):12722–33.